TERIZIDONE IS WHO CATEGORIZED GROUP IV ANTI TB DRUG. IT IS AN ANTIBIOTIC EFFECTIVE AGAINST MYCOBACTERIUM TUBERCULOSIS AND ALSO M. AVIUM FOR THE TREATMENT OF TUBERCULOSIS, BOTH PULMONARY AND EXTRA PULMONARY. IT IS CLASSIFIED AS A SECOND-LINE DRUG. TERIZIDONE HAS POTENT AND EXTENDED ANTIMYCOBACTERIAL
ACTIVITIES, AND EXERTS REMARKABLE EFFECTS AGAINST NOT ONLY STRAINS CAUSING PULMONARY TUBERCULOSIS OR URINARY TRACT INFECTIONS
BUT ALSO STRAINS WHICH HAVE BECOME RESISTANT TO EXISTING ANTIMYCOBACTERIAL DRUGS.
ITS MODE OF ACTION IS SIMILAR TO CYCLOSERINE I.E. IT ACTS BY INHIBITING CELL WALL SYNTHESIS BY COMPETITIVELY INHIBITING TWO ENZYMES, L-ALANINE RACEMASE AND D-ALANINE LIGASE, THEREBY IMPAIRING PEPTIDOGLYCAN FORMATION NECESSARY FOR BACTERIAL CELL WALL SYNTHESIS.